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ABSTRACT
Background: The clinical usefulness of fixed-dose maintenance therapy with salmeterolfluticasone (SFC)
and budesonideformoterol combination inhaler (BUDFM) has been established, though evidence of the long-
term anti-inflammatory effects of these 2 inhalers are limited.
Methods: Patients with moderate persistent adult asthma who had received SFC 50250 μg bid with well-
control status were recruited. After switching to 8-week therapy with fixed-dose BUDFM 4 puffs (64018 μg)
(phase-1), patients chose either SFC or BUDFM. FeNO and ACT score were evaluated every 8 weeks until
the end of the 52-week treatment period for both treatment groups (phase-2).
Results: In total, 103 patients were examined: BUDFM was chosen by 34 patients (BUDFM group), while
SFC was chosen by 23 (SFC group). Thirty-six received SFC consistently from the beginning of the study (con-
trol). Patients in the BUDFM and SFC groups showed significant improvements in ACT scores and FeNO lev-
els in phase-1; these beneficial effects persisted for 52 weeks in the BUDFM group. On the other hand, in the
SFC group, although the FeNO level decreased from 54.3 ± 26.4 ppb to 41.9 ± 18.3 ppb in phase-1, it in-
creased to 54.5 ± 26.2 ppb, a level similar to the baseline prior to the beginning of BUDFM therapy, at 8 weeks
in phase-2, and remained at 50-odd ppb thereafter.
Conclusions: These results suggest that maintenance therapy with fixed-dose BUDFM is a useful treatment
option exerting an airway anti-inflammatory effect for a period as long as 1 year, even for asthmatics who could
not accomplish total control with SFC.
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INTRODUCTION
According to asthma treatment guidelines such as
GINA1 and Japanese guideline,2 a long-acting β2 ago-
nists (LABA) are deemed as most favorable add-on
drugs to inhaled corticosteroid (ICS) in patients
whose asthma is not adequately controlled on low or
medium dose ICS which is the first choice medica-
tion for long-term asthma control. Combination prod-
ucts, containing both an ICS and LABA in one in-
haler, have been used for more than 10 years and two
ICSLABA combination inhalers - budesonidefor-
moterol (BUDFM) and salmeterolfluticasone
(SFC) - are currently available. They have contrib-
uted to improvement of patient acceptability and ad-
herence in taking both therapies,3,4 and highly effec-
tive at providing early and sustained amelioration in
asthma control for patients symptomatic on ICS. Even
with such treatments, however, asthma control could
be suboptimal. Bateman and coworkers reported that
the patients who could attain “total control” in which
asthma symptoms are completely controlled, by long-
term treatment with SFC remain to 50% or less.5 The
patient who could not accomplish “total control” re-
mains symptomatic and it is thought that inflamma-
tion also exists on its airway. It has been pointed out
that inflammation may be present not only in central
but also in peripheral airways. The mean diameter of
particles in a BUDFM combination dry powder in-
haler is reported to be 2.4 μm,6 which is smaller than
the corresponding particle diameter (4.4 μm) of SFC
dry powder.7 Therefore, the probability of BUDFM
particles reaching the peripheral airway is considered
to be higher than for SFC particles.8 In fact, a high
anti-inflammatory effect of BUDFM has occasionally
been reported,9-13 but none of these studies followed
the effect of BUDFM for more than a short period of
approximately 8-16 weeks. Long-term, approximately
1 year, clinical effects of BUDFM fixed-dose mainte-
nance therapy and SFC therapy have been compared.
However, all of these comparisons focused mainly on
clinical symptoms as the evaluation items in view of
preventing acute exacerbation,14-19 and the reported
results are not consistent. Thus, long-term compara-
tive data on anti-inflammatory effects on the airway
are limited.
We carried out a 52-week change-over before-and-
after trial that evaluated changes in exhaled nitric ox-
ide (FeNO) as an index of airway inflammation, aim-
ing at comparison of the therapeutic effects on airway
inflammation in long-term management with BUD
FM and SFC. Randomized controlled trials are defi-
nitely superior to studies of other designs when com-
paring the effects of different drugs. However, consid-
ering that inhalation treatment was to be continued
for approximately 1 year in this study, it was likely
that treatment preference would affect the study re-
sults even with repeated guidance on inhalation ther-
apy. We thus considered 1-year treatment with a drug
chosen by the patients themselves to likely lead to
better adherence to the treatment protocol and be
closer to real-world situations. Therefore, the effects
of two types of inhalers were compared by allowing
patients to choose the inhaler that they preferred.
METHODS
The subjects of the study were adult outpatients of
the National Center for Global Health and Medicine
(Tokyo) or at Kohnodai Hospital (Chiba), aged 20
years or older, with persistent moderate asthma. The
diagnosis of asthma was defined as the presence of
compatible clinical history and pulmonary function
tests demonstrating variable airflow obstruction by
means of bronchodilator responsiveness, or by dem-
onstrating bronchial hyperreactivity using meth-
acholine challenge. The asthmatics treated for at
least 6 months with SFC 50250 μg Diskus (dry pow-
der inhaler) bid therapy (GINA treatment steps 3-4),
in whom the disease was “well-controlled” or “totally
controlled”, i.e., an asthma control test (ACT) score
of 20-25 points, were eligible. Current smokers, those
who had a smoking history (smoking index >400)
and patients with suspected COPD with either non
reversible airflow obstruction or obvious low attenu-
ation area on chest CT were excluded from the analy-
sis. Moreover patients who had a respiratory tract in-
fection within the last 4 weeks were also excluded.
Patients with allergic rhinitis were eligible if their
rhinitis symptoms had fully settled down.
This was a non-blind change-over before-and-after
comparative study. Written, informed consent was
obtained from each patient. Patients chose to con-
tinue SFC 50250 μg bid therapy (control group) or
change to BUDFM (dry powder inhaler) 64018 μg
therapy (2 puffs twice daily) as the first step. Patients
who chose BUDFM therapy received 8-week fixed-
dose treatment with BUDFM (phase 1). As the sec-
ond step after phase 1, patients chose to continue
BUDFM 4-puff fixed-dose therapy (BUDFM
group) or to return to SFC 50250 μg bid therapy
(SFC group), and then continued the treatment they
chose for 52 weeks (phase 2). The maintenance dose
of BUDFM was left unchanged. Combined use of a
controller other than an ICSLABA combination in-
haler was permitted, but changing the dosage of any
drugs during the study period was not permitted. Pa-
tients who received an increased maintenance dose
or 5-day or longer systemic steroid therapy because
of acute exacerbation or for any other reason were re-
garded as study drop-outs.
Changes in the FeNO level were observed as the
primary endpoint. The ACT score, the frequency of
using short-acting β2-agonists (SABA) for additional
relief of symptoms, and medication side effects were
also examined. The patients’ conditions were evalu-
ated in the outpatient clinic at intervals of 8-12 weeks.
Long-Term Effect of Fixed-Dose BUDFM
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Table　1　Baseline characteristics of the study population
BUD/FM group SFC 250 group Control group P value
Number 34 23 36 -
Male/Female 14/20 15/8 20/16 0.04*
Age (y.o) 59.4 ± 8.6 56.1 ± 12.5 54.4 ± 16.7 0.26
Ex/never-smoker 17/17 14/9 21/15 0.87*
Allergic rhinitis (-)/(+) 15/19  11/12 15/21 0.78*
Treatment LTRA 14  8 10 0.49*
Theophyline  5  4  7 0.87*
Asthma duration (yrs) 15.3 ± 10.5 14.9 ± 11.2 15.8 ± 10.4 0.85
FEV1.0 (L) 1.78 ± 0.83 2.27 ± 0.83 2.45 ± 0.77 0.03
FEV1.0% 68.9 ± 9.6 73.9 ± 13.2 76.1 ± 11.8 0.05
% FEV1.0 (% predicted) 76.3 ± 8.4 84.1 ± 10.6 85.7 ± 9.9 0.04
ACT score 21.9 ± 1.6 23.2 ± 1.5 23.2 ± 1.4 0.01
FeNO (ppb) 49.6 ± 24.9 54.5 ± 26.9 42.4 ± 23.5 0.37
Data are presented as mean ± SD. P-values of chi-square test, and Fisher exact test* are shown.
At every visit to the outpatient clinic, patients were
given guidance on inhalation therapy, and examined
for the remaining quantity of inhaler to determine its
consumption during the previous 8 weeks and to cal-
culate the rate of adherence to inhalation therapy.
Pulmonary function tests (FVC, FEV1.0, MMF etc.)
were also carried out using computerized equipment
(model CHESTAC-8100; CHEST MI, Inc., Tokyo, Ja-
pan) before and after the study. FeNO was measured
using NIOX-MINO (Aerocrine Ltd., Solna, Sweden)20
before any forced expiratory maneuvers, two read-
ings were obtained and the mean value was used for
the analysis. All the medications for maintenance
therapy were stopped 12 hours before FeNO and spi-
rometry measurements, and these measurements
were performed in the same order at similar times of
the day before inhalation of the morning dose.
Performance of this clinical study was approved by
the Ethics Committee of the National Center for
Global Health and Medicine (2009-795). Clinical trial
registration number was UMIN000010151. All meas-
urement values are presented as means ± SD. Differ-
ences between populations were analyzed for signifi-
cance using chi-square test (without continuity cor-
rection), and Fisher’s exact test. Comparisons be-
tween baseline and each measured values were ana-
lyzed using repeated-measures ANOVA, paired Stu-
dent t-test, and McNemar test.
RESULTS
PATIENT CHARACTERISTICS
Although a total of 103 patients participated in the
study, 2 patient dropped out because of an adverse
event, and 8 dropped out due to asthma exacerbation,
data from 93 patients were thus analyzed. Among
these 93 patients, the male to female ratio was 49 to
44, the mean age was 56.5 ± 12.5 years (24-78 years),
and the mean disease duration was 15.3 ± 11.1 years.
Ex-smokers were 52 patients (56%) with mean smok-
ing index 225 ± 123. Concomitant medication was leu-
kotriene receptor antagonist in 32 patients and a theo-
phyline preparation in 16. These background factors
showed no significant differences among the three
groups (Table 1).
The BUDFM group was comprised of 34 patients,
and the SFC group of 23. The control group was com-
prised of 36 patients who chose at the beginning of
the study to continue using SFC. Women signifi-
cantly outnumbered men in the BUDFM group. The
reasons for choosing BUDFM therapy included that
they were aware of improved control that clearly sur-
passed the benefits of SFC and they also acknowl-
edged the better portability of BUDFM. In addition,
in the BUDFM group, FEV1.0 was significantly
lower, and the ACT score at baseline was low, indicat-
ing that patients who had not obtained adequate con-
trol with the conventional treatment were predomi-
nant in this group. In SFC group, the reason for re-
turning to SFC therapy included mainly that they
could not recognized better control with BUDFM
and wanted to continue their familiar medication and
devices. Drop-out due to asthma exacerbation oc-
curred in 2 patients in the BUDFM group, 3 cases in
the SFC group, and 3 cases in the control group,
showing no significant differences among the three
groups (Fig. 1).
FRACTIONAL EXHALED NITRIC OXIDE (FeNO)
The primary endpoint, the FeNO level, was signifi-
cantly improved at the end of phase 1 in both groups,
showing improvement from 49.5 ± 24.5 ppb to 34.4 ±
12.6 ppb in the BUDFM group, and from 54.3 ± 26.7
ppb to 41.7 ± 18.8 ppb in the SFC group (p < 0.01,
ANOVA). In the BUDFM group, the beneficial ef-
fect persisted during the phase 2 period, with levels
equal to or lower than 38 ppb, varying within the nor-
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Fig.　1　Study design and patient selection.
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Fig.　2　The changes in mean fractional exhaled nitric oxide (FeNO) values. *p < 
0.05 vs 8 weeks, ANOVA.
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mal range for Japanese people.21 The FeNO level at 1
year in this group was 36.8 ± 14.3 ppb. On the other
hand, in the SFC group, the FeNO level was 41.9 ±
18.3 ppb at the beginning of phase 2, but was signifi-
cantly increased to 54.5 ± 26.2 ppb 8 weeks later,
showing worsening of the patients’ conditions (p <
0.05, ANOVA), and then returned to the baseline
level prior to BUDFM therapy. The level remained
over 50-odd ppb thereafter. In the control group, the
FeNO level varied between 40.4 ± 19.5 ppb and 46.8 ±
29.3 ppb in both phase 1 and phase 2, showing no sig-
nificant changes (Fig. 2).
Respiratory function tests included measurements
of FVC, FEV1.0, and MMF at three time points, i.e.,
before the study, at the end of phase 1, and at the end
of phase 2. There were no significant changes in any
measurement item at any of these three time points
(Table 2).
ASTHMA CONTROL TEST
Asthma control test (ACT) scores also showed simi-
lar variations. In both the BUDFM group and the
SFC group, there was significant improvement at the
end of phase 1. Although the beneficial effect per-
sisted during the phase 2 period in the BUDFM
group, there was a significant increase in the SFC
group at 16 weeks after phase 2 (Fig. 3). Total control
represented by a full ACT score of 25 was found in
only 13 (13%) patients at the time of entry. In the
BUDFM group, the achievement rate was 9% in-
Long-Term Effect of Fixed-Dose BUDFM
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Table　2　The changes of Spirometry parameters
BUD/FM group
(n = 34)
SFC 250 group
(n = 23)
Control group
(n = 36)
0 wk 8 wks 60 wks 0 wk 8 wks 60 wks 0 wk 8 wks 60 wks
FVC 2.62 ± 0.78 2.72 ± 0.59 2.75 ± 1.11 3.07 ± 1.01 3.03 ± 1.33 2.87 ± 1.27 2.81 ± 1.01 2.87 ± 1.22 2.77 ± 0.97
FEV1.0 1.78 ± 0.83 1.84 ± 0.52 1.88 ± 0.87 2.27 ± 0.83 2.35 ± 0.93 2.33 ± 0.72 2.45 ± 0.77 2.35 ± 0.93 2.33 ± 0.72
FEV1.0% 68.9 ± 9.6 67.7 ± 9.7 68.4 ± 13.5 73.9 ± 13.2 76.5 ± 16.2 77.4 ± 18.4 76.1 ± 11.8 76.5 ± 16.2 79.4 ± 11.7
MMF 1.62 ± 0.75 1.71 ± 1.39 1.65 ± 1.29 1.68 ± 0.98 1.61 ± 1.15 1.73 ± 1.31 1.58 ± 0.98 1.66 ± 1.14 1.71 ± 1.42
V50 1.44 ± 1.08 1.64 ± 1.52 1.57 ± 1.21 1.59 ± 0.87 1.67 ± 0.74 1.62 ± 1.11 1.49 ± 0.87 1.54 ± 0.71 1.49 ± 0.96
V25 0.69 ± 0.77 0.77 ± 0.96 0.74 ± 0.99 0.91 ± 0.96 1.11 ± 1.36 1.07 ± 0.98 0.81 ± 0.96 0.94 ± 1.29 0.89 ± 1.11
Data are presented as mean ± SD. All the values revealed no signifi cant using ANOVA.
Fig.　3　The changes in mean Asthma Control Test (ACT) score. *p < 0.05 vs 8 
weeks, ANOVA.
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itially and then increased to 35% at the end of phase 1,
showing a significant improvement (p < 0.01, McNe-
mar test). Thereafter, the achievement rate increased
gradually to reach 70% at 24 weeks. Although the
achievement rate decreased gradually thereafter, it
remained at 46% even at the end of phase 2. On the
other hand, in the SFC group, the rate of achieving
total control increased rapidly from 14% to 64% in
phase 1, and also showed a gradual increase up to the
24th week (70%), although the achievement rate de-
creased after the 36th week and then returned to the
baseline level. In the control group, the rate of total
control was 20% before the study and was maintained
between 40% and 50% throughout most of the phase 2
period.
FeNO value correlated with not only ACT Question
4 (p = 0.465, p < 0.03) but also total score of ACT (p =
0.315, p < 0.05) in total study period. There were
good correlations between FeNO and ACT score
changes in phase 1 both BUDFM and SFC group (r
= 0.715, 0.662, p < 0.03). FeNO also correlated with
ACT score in phase 2 (when comparing baseline and
end of phase 2) only in BUD-FM group (r = 0.447, p <
0.05), but correlation coefficient was lower than those
in phase 1, while it was not found by SFC treatment
(r = 0.169, p = 0.35).
RELIEVER USE AND ADHERENCE
Figure 4 shows the frequency of using the SABA for
additional symptom relief (mean number of uses
week during the 2 weeks prior to each evaluation
point). There was also a similar trend in the fre-
quency of SABA use. In other words, in the BUDFM
group, the number of SABA uses was 3.11 ± 1.59
week at the time of entry but was significantly re-
duced to 0.39 ± 0.56week at the end of phase 1 (p <
0.01, paired Student t-test), and maintained at less
than 1week thereafter. In contrast, there were no
significant changes in the frequency of SABA use in
either the SFC group or the control group. The fre-
quency of SABA use correlated with not only ACT
Question 4 (p = 0.785, p < 0.01) but also total score of
ACT (p = 0.515, p < 0.05). Thereafter, the frequency
of SABA use correlated with FeNO (p = 0.385, p <
0.05).
The adherence rates at the time of entry ranged
from 77% to 81% in the three groups, showing no sig-
nificant intergroup differences. The adherence rate
Hojo M et al.
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Fig.　4　The changes in mean weekly SABA use. *p < 0.01 vs -2-0 weeks, paired t-test.
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increased significantly during phase 1 in all three
groups (p < 0.03, ANOVA). In both BUDFM group
and SFC group, the adherence rate was increased to
approximately 90% at the end of phase 1, but then
gradually decreased, reaching 85% at the end of
phase 2, with no significant differences between
groups. In the control group, the adherence rate var-
ied between 83% and 88% throughout the study.
SAFETY
In regard to safety, among the 103 patients enrolled
in this study, 2 patient dropped out because of a
cough associated with BUDFM inhaler. The other
adverse events were hoarseness in 2 patients, mild
palpitation during body motion in 5, and unpleasant
sensation (bitter taste) during inhalation in 4 in the
BUDFM group. All of these patients were able to
continue the study without difficulty.
DISCUSSION
In order to verify the long-term inhibitory effect of
BUDFM on airway inflammation, we examined the
effects of treatment with fixed dose BUDFM (640
18 μgday) during an approximately 1 year period in
patients with moderate persistent asthma controlled
by SFC 50250 μg bid. The therapeutic effects were
assessed in terms of the FeNO level and the ACT
score. Fixed-dose BUDFM therapy achieved signifi-
cant improvements in both the FeNO level and the
ACT score. The rate of achieving total control in
terms of the ACT score was also significantly higher,
showing that this therapy can bring about total con-
trol including inhibition of airway inflammation in
many patients. This study adopted a design by which
patients chose the inhaler they preferred. Among pa-
tients who chose BUDFM after maintenance ther-
apy with SFC, there were many individuals in whom
control was inadequate, showing persistent obstruc-
tive respiratory disorder associated with significantly
lower FEV1.0 and ACT scores. In other words, the
ACT score was significantly higher (p < 0.03, Student-
t test) at 0 week in the control group, suggesting that
persistent use of SFC was chosen because of the
good control status achieved.
In this study, the fixed-dose BUDFM therapy
(64018 μgday) produced no significant improve-
ment in FEV1.0 or peripheral airway parameters such
as25 on respiratory function tests. A recent Japanese
study that used a similar change-over before-and-after
comparative design with the BUDFM11 reportedly
achieved significant improvement in not only periph-
eral airway resistance determined by impulse oscillo-
metry but also in50 and25, even though the study
period was only 4 weeks. The subjects of their study
were asthma patients with disease durations of 4-8
years, shorter than that in our present study, suggest-
ing a high likelihood that there was remaining re-
versibility of peripheral airway remodeling in their
cases. Because our study targeted patients with rela-
tively advanced airway remodeling in whom the
FEV1.0% was 71.5% on average, it can be inferred that
their responses would not have been adequate to pro-
duce improvement of these indices. It is of great sig-
nificance that the fixed-dose BUDFM therapy
achieved good clinical effects and a persistent anti-
inflammatory effect on the airways for a period as
long as 1 year in such patients with advanced disease.
In recent years, it has been advocated that treat-
ment of asthma focus on both aspects of current con-
trol such as stabilization of clinical symptoms and
varying respiratory functions, and the reduction of fu-
ture risk caused by constant respiratory impairment
Long-Term Effect of Fixed-Dose BUDFM
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due to recurrent exacerbations or persistent unstable
control.22-24 Although which indices should be used
for evaluation of the future risk of asthma is contro-
versial, peripheral airway lesions and remaining air-
way inflammation are considered to be important fac-
tors.23 In general, it is said that the FeNO level corre-
lates with eosinophilic inflammation of the airway if
factors, such as airway neutrophilic infection and
rhinitis, which may exert an influence are excluded.25
However, there may be a dissociation between clini-
cal control status and the FeNO level, and it has been
reported that adding evaluation of the FeNO level as
an index to guideline-based treatment failed to im-
prove control status.26,27
In our present study, the FeNO level decreased in
49 of 57 patients at 8 weeks after switching from SFC
to the fixed-dose BUDFM 4-puff therapy, and there
was significant overall improvement. There were 3
possible mechanisms to explain these improvements.
First, as mentioned previously, this may be explained
by the small and proper particle size of both ICS and
LABA in the BUDFM, which facilitates drug parti-
cles reaching the peripheral airway. Small particle
size had another advantage for the patients in our
study in whom not only FEV1.0% but also inhalation
flow rate were low. Second, the intrinsic efficacy of
the different LABAs in two medications could be im-
portant factor. Intrinsic efficacy refers to the ability of
a drug to activate its receptor, without regard for
drug concentration.28 It is reported that LABAs that
have greater intrinsic efficacy (e.g. formoterol) could
be more effective in causing beta2-adrenergic action
than those agents that have less intrinsic efficacy
(e.g. salmeterol).29 Third, the property of the BUD
FM allowing rapid onset of the bronchodilator effect
of LABA and thus promoting a positive perception of
the inhalation effect contributed to the improved ad-
herence.30 It can thus be inferred that our study de-
sign, permitting patients to choose the inhaler that
they preferred while continuing treatment, improved
adherence, thereby achieving a better anti-
inflammatory effect on the airway.
As shown in Figure 2 and 3, in phase 1, not only
ACT score but also FeNO level improved at 8 weeks
after switching from SFC to the fixed-dose BUDFM
4-puff therapy in almost all the patients. The reason
why the coefficient of correlation in SFC group was
lower than BUDFM group in phase 1 could be that
the baseline ACT score in BUDFM group was sig-
nificantly lower than SFC group, so that changes of
ACT score were larger in BUDFM group in com-
parison with those in SFC group. In contrast, compar-
ing ACT score and FeNO value between baseline and
end of phase 2, both parameters improved in BUD
FM group, while in SFC group, there were no signifi-
cant changes. That is a reason why there was a corre-
lation between FeNO and ACT by BUDFM treat-
ment continuation, and that it was not found by SFC
treatment. The continuation treatment for more than
1 year by BUDFM could preserve lower level of
FeNO that was an index of the airway inflammation in
asthma and was able to inhibit the frequency of SABA
use that could be an index of the current asthma con-
trol. In addition, it was reported that there was an as-
sociation between the frequency of SABA use and
FeNO level, and the improvement of the frequency of
SABA use linked FeNO level in the time course for
treatment by BUDFM more than 1 year in this
study, while these tendency were not found in the
SFC treatment continuation. In other words, it was
shown that the likelihood which the long-term man-
agement of asthma by BUDFM could be an appro-
priate treatment preference for the achievement of
current control and the reduction of future risk.
In recent years, potent anti-inflammatory effects of
the fixed-dose BUDFM 4-puff (64018 μg) therapy
on the airway, as examined during short periods of 4-
12 weeks, have occasionally been reported.11-13,31 In
general, on a global scale, BUDFM is mainly used
for long-term management with single-inhaler main-
tenance and reliever therapy (SMART) in which the
inhalation dose is adjusted according to the patient’s
symptoms. Therefore, although there have been a
number of reports on preventive effects against acute
exacerbation, reports on the anti-inflammatory effect
on the airway have been limited. Conversely, some
reports have suggested airway inflammation to be ex-
acerbated by prolonged SMART.32,33 In Japan, al-
though insurance coverage of SMART was not ap-
proved until 2012, it is assumed that BUDFM de-
scribed herein will become the mainstay of long-term
maintenance therapy in the near future. The results
of our present study suggest the potent long-term
therapeutic effect of fixed-dose BUDFM medium-
dose inhalation therapy on airway inflammation. Even
when employing SMART, it may be necessary to pro-
vide treatment that takes airway inflammation into ac-
count, e.g., by implementing the fixed-dose (64018
μg) inhalation therapy for 8 weeks or more, in pa-
tients in whom the frequency of BUDFM use for
symptom relief is increased, suggesting worsening of
airway inflammation.
The results of this study should be considered
along with the limitations. First, the study is small,
with about 30 patients per group. Second, this study
is not designed as randomized study and each study
group is obviously biased. During the study period,
the patients have chosen their favorite ICSLABA two
times at their decision. This could be a major weak-
ness of this study. The adherence rates of inhalation
therapy are not different in each groups throughout
the study, still there are substantial bias inherent in
this study and it may be difficult to quantitate exactly
the primary outcome of this study. However, a prag-
matic trial34 and a real-world observational study35
have shown that prolonged use of inhalation therapy
Hojo M et al.
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results in a decrease in the ICS adherence rate to less
than 50%. Therefore, in patients in whom adherence
to inhalation therapy remains poor despite various
measures being taken, patient-oriented therapy in
which they could choose their favorite inhaler by
themself may be more useful in real-world clinical
setting.
It is of major clinical significance that the present
results suggest that the anti-inflammatory effect of
the BUDFM 4-puff (64018 μg) therapy on the air-
way persists for at least 1 year. More specifically,
from the aspects of current control and future risk re-
duction, the two major concepts in recent asthma
care, this therapy is not only extremely useful for cur-
rent control in view of the high total control achieve-
ment rate but also contributes to the reduction of fu-
ture risk in terms of its anti-inflammatory effect on
the airway. Although the position of SMART therapy
with BUDFM may be established in the near future
in Japan, 4-puff fixed-dose inhalation therapy should
be evaluated from the viewpoint of more prolonged
inhibition of airway inflammation. It is important to
further investigate the efficacy and safety of pro-
longed use of BUDFM on airway inflammation,
through clinical experience with patients suffering
from different severities of asthma.
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